drugset / Trial / NCT07502222
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.
Timeline
- Start
- 2026-04-07
- Primary completion
- 2027-11
- Completion
- 2028-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK139 | Unknown | — | Subcutaneous |